期刊文献+

RET/PTC1重排和BRAF^V600E突变甲状腺乳头状癌细胞系原位裸鼠模型比较 被引量:1

Comparison of orthotropic models of RET/PTC1 rearrangement and BRAF V600E mutation papillary thyroid cancer cell lines in nude mice
分享 导出
摘要 目的比较RET/PTC1重排和BRAF^V600E突变甲状腺乳头状癌细胞系的原位裸鼠模型。方法甲状腺乳头状癌细胞系TPC-1、BHP5-16和BHP2-7经实时定量PCR和DNA测序鉴定RET/PTCI重排和BRAF“加突变细胞株类型。3株细胞分别以2×10^5/只原位接种于balb/c裸鼠甲状腺被膜下,分别在4、12周处死裸鼠,剥离甲状腺肿瘤称重,并测定血清甲状腺激素水平。结果经实时定量PCR鉴定TPC-1和BHP2-7。细胞为RET/PTC1重排,且BHP2-7细胞RET/PTC1表达量远高于TPC-1细胞。DNA测序结果显示BHP5-16细胞为BRAF^V600E突变,TPC-1和BHP2-7细胞非BRAF^V600E突变。3组原位裸鼠模型表现各有不同。TPC-1和BHP5-16组成瘤率为100%,但BHP5-16组肿瘤生长迅速,肿瘤重量远大于TPC-1组。同时二者甲状腺激素水平的变化相同,4周时正常而12周时显著下降(P〈0.05)。然而BHP2-7组的成瘤率仅为6.25%,其甲状腺激素水平与正常对照组相比差异未见统计学意义(P〉0.05)。结论RET/PTCI重排和BRAF^V600E。突变甲状腺乳头状癌细胞系在原位裸鼠模型中表现不同,BRAF^V600E突变具有更明显提高模型成瘤率和促进肿瘤生长的作用。同时值得关注的是中晚期甲状腺肿瘤会导致机体甲状腺功能的破坏。 Objective To observe and compare the different orthotopic models of papillary thyroid cancer (PTC) cell lines of RET/PTCI rearrangement and BRAFV600E mutation in nude mice. Methods Human PTC cell lines TPC-1, BHP5-16 and BHP2z were used. The genotypes of RET/PTCI rearrangement and BRAFV600E mutation were determined by realtime-PCR and DNA sequencing analysis. The cells (2 × 10^5 ) were injected into the thyroid gland of nude mice. The nude mice were executed at 4th, 12th week, and then their thyroid tumors were removed and weighed. The levels of thyroid hormone were detected using chemiluminescent immunoassay. Results Both TPC-1 and BHP2_7 cells were identified as RET/PTC1 rearrangement by real time-PCR, and the expression of RET/PTCI rearrangement in BHP2-7 cell was higher than that of TPC-I cell. BRAFV600E mutation was found in BHP516 cell by DNA sequencing analysis, but was not found in TPC-1 and BHP2-7 cells. There were different characteristics in three orthotnpic nude model groups. Tumorigenic rates of TPC-1 and BHPs ,6 groups were 100%, but the growth of tumor was more rapid in BHP5-16 group than that in TPC-1 group, with more weight tumor. The changes of thyroid hormone levels in BHP5 -16 group and TPC-1 group were the same, which were normal at 4th week and sharply decreased at 12 th week(P〈0.05 ). However, the tumorigenic rate of BHP2z group was only 6.25%. Compared with normal contrnl group, there was no statistical difference in the levels of thyroid hormone in BHP27 group ( P〉0.05 ). Conclusions It showed difference in the orthotopic models of PTC cell lines of RET/PTC1 rearrangement and BRAF^V600E mutation in nude mice. BRAF^V600E mutation has obvious impacts on increasing tumorigenic rate and promotion of tumor growth in the orthotopic model. It should not be ignored that advanced thyroid tumor will lead to the destruction of thyroid function.
作者 叶艳 武学润 赵树君 李永梅 孙毅娜 林来祥 阎玉芹 陈祖培 Ye Yan , Wu Xuerun, Zhao Shujun, Li Yongmei, Sun Yina, Lin Laixiang, Yan Yuqin , Chen Zupei. (Key Laboratory of Hormones and Development ( Ministry of Health ) , Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China)
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2016年第1期62-66,共5页 Chinese Journal of Endocrinology and Metabolism
基金 国家自然科学基金项目(81001226)志谢感谢浙江医科大学滕理送、王伟斌老师给予的极大帮助.
关键词 甲状腺乳头状癌 原位裸鼠模型 RET/PTC1重排 BRAF^V600E突变 Papillary thyroid cancer Orthotopic nude mouse model RET/PTCI rearrangement BRAF^V600E mutation
作者简介 通信作者:武学润,Email:wuhx2006@yeah.net
  • 相关文献

参考文献12

  • 1Piscazzi A, Costantino E, Maddalena F,et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines[J]. J Clin Endocrinol Metab, 2012,97(6):898-906. 被引量:1
  • 2Bansal M, Gandhi M, Ferris RL,et al. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma[J]. Am J Surg Pathol, 2013,37(10):1586-1591. 被引量:1
  • 3Henderson YC, Chen Y, Frederick MJ, et al. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo[J]. Mol Cancer Ther, 2010,9(7):1968-1976. 被引量:1
  • 4王萍,王颜刚,赵文娟,付浴东,王娈,王芳,赵世华,甲状腺乳头状癌BRAF基因突变及RET/PTC基因重排与血小板源性生长因子B表达的相关性研究[J].中华内科杂志,2012,51(12):987-992. 被引量:3
  • 5Rahman MA, Salajegheh A, Smith RA, et al. B-Raf mutation: A key player in molecular biology of cancer[J]. Exp Mol Pathol, 2013,95(3):336-342. 被引量:1
  • 6James J, Ruggeri B, Armstrong RC,et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity[J]. Mol Cancer Ther, 2012,11(4):930-941. 被引量:1
  • 7Han SA, Park WS, Jang JH, et al. BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer[J]. Ann Surg Treat Res, 2014,87(4):174-179. 被引量:1
  • 8McKelvie PA, Chan F, Yu Y,et al. The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry[J]. Pathology, 2013,45(7):637-644. 被引量:1
  • 9Endo T, Kobayashi T. Concurrent overexpression of RET/PTC1 and TTF1 confers tumorigenicity to thyrocytes[J]. Endocr Relat Cancer, 2013,20(6):767-776. 被引量:1
  • 10Couto JP, Almeida A, Daly L, et al. AZD1480 blocks growth and tumorigenesis of RET-activated thyroid cancer cell lines[J]. PLoS One, 2012,7(10):e46869. 被引量:1

二级参考文献34

  • 1Peyssonnaux C, Eyohene A. The Raf/MEKIERK pathway: new concepts of activation. BioI Cell, 2001 , 93 :53-62. 被引量:1
  • 2Nakazawa T, Kondo T, Kobayashi Y, et al. RET gene rearrangements (RET/PTCI and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (J apan). Cancer, 2005 , 104 :943-951. 被引量:1
  • 3KnaufJ A, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res, 2005, 65 :4238-4245. 被引量:1
  • 4Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer, 2005,12 :245-262. 被引量:1
  • 5Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta, 2003, 1653: 25-40. 被引量:1
  • 6Garnett MJ , Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell, 2004, 6: 313-319. 被引量:1
  • 7Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer, 2006, 13: 455- 464. 被引量:1
  • 8Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.J Clin Endocrinol Metab, 2003, 88: 5399-5404. 被引量:1
  • 9Kim KH, Kang OW, Kim SH, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Y onsei MedJ , 2004, 45 :818-821. 被引量:1
  • 10Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.J Clin Endocrinol Metab, 2003, 88: 4393 -4397 . 被引量:1

共引文献2

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈